ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) and Heron Therapeutics (NASDAQ:HRTX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for ANI Pharmaceuticals and Heron Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANI Pharmaceuticals | 0 | 4 | 4 | 0 | 2.50 |
| Heron Therapeutics | 1 | 3 | 1 | 0 | 2.00 |
ANI Pharmaceuticals currently has a consensus price target of $103.00, indicating a potential upside of 30.63%. Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 640.74%. Given Heron Therapeutics’ higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than ANI Pharmaceuticals.
Volatility & Risk
Profitability
This table compares ANI Pharmaceuticals and Heron Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals | 11.07% | 27.37% | 10.47% |
| Heron Therapeutics | -22.52% | -293.02% | -10.00% |
Insider and Institutional Ownership
76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares ANI Pharmaceuticals and Heron Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ANI Pharmaceuticals | $883.37 million | 2.05 | $78.34 million | $4.64 | 16.99 |
| Heron Therapeutics | $154.90 million | 0.33 | -$20.19 million | ($0.19) | -1.42 |
ANI Pharmaceuticals has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
ANI Pharmaceuticals beats Heron Therapeutics on 11 of the 14 factors compared between the two stocks.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
